Cannara Biotech Q3 revenue tops estimates on expanded distribution
Cannara Biotech Q3 revenue tops estimates on expanded distribution
Overview
Canada cannabis producer's fiscal Q3 total revenues rose 16% yr/yr
Adjusted EBITDA for fiscal Q3 rose 11% yr/yr to C$8.5 mln
Company expanded distribution and increased cultivation capacity with two new grow zones
Outlook
Cannara expects to activate four more grow zones in fiscal 2027, raising capacity to 75,000 kg
Company anticipates launching Nugz Ampersand products, pending regulatory approvals and provincial listings
Cannara aims to maintain or grow retail market share and expand national distribution
Result Drivers
HIGHER SALES VOLUMES - Co said revenue and gross profit growth were driven by increased sales volumes and expanded production capacity following activation of new grow zones
PRODUCT INNOVATION - Deeper market penetration, product innovation and expanded product formats contributed to sales growth, per management
DISTRIBUTION EXPANSION - Co expanded national distribution and retail penetration, with products exceeding 49,000 points of distribution and increased share of retail listings
Company press release: ID:nGNX5W2vsM
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Total Revenues | Beat | C$31.80 mln | C$31.23 mln (3 Analysts) |
Q3 EPS |
| C$0.05 |
|
Q3 Net Income |
| C$4.80 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Cannara Biotech
See all newsBrief: Cannara Biotech - Enters Amended Syndicated Credit Agreement With BMO And Td
Cannara Biotech Q3 revenue tops estimates on expanded distribution
Canada Research Roundup: Cannara Biotech ,Equinox Gold , Winpak
Brief: Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced At C$2.10 Per Common Share
Brief: Cannara Biotech Delivers Q4